Race Oncology (ASX:RAC) filed an application with the Bellberry Human Research Ethics Committee for a phase 1 trial investigating the use of the RC220 bisantrene in combination with doxorubicin to potentially treat solid tumors, according to a Thursday filing made with the Australian bourse.

Once approved, the biopharmaceutical firm will activate the first trial site in New South Wales, with an additional 10 sites to follow, the filing said.

Patient recruitment for the trial is scheduled for the first quarter of next year, the filing added.

The company's shares surged past 9% in recent Thursday trade.

Price (AUD): $1.41, Change: $+0.12, Percent Change: +9.33%